Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
Conditions
Keywords
Interleukin 1 receptor antagonist, IL-1 receptor antagonist, Kineret, anakinra, Adult-Onset Still's Disease, Systemic Juvenile Idiopathic Arthritis
Brief summary
The aim of this study is to demonstrate the efficacy and to evaluate the safety, pharmacokinetics (PK) and immunogenicity of anakinra in patients with newly diagnosed Still's disease, including SJIA (Systemic juvenile idiopathic arthritis) and AOSD (Adult-onset Still's disease).
Detailed description
The study consists of a 12-week, randomized, double-blind, placebo controlled period with two dose levels of anakinra and a 4-week safety follow-up after last dose of investigational medicinal product (IMP). The primary endpoint will be evaluated at Week 2. Sustained efficacy and time to study drug discontinuation will be evaluated during the full study period. A screening visit is optional and may be done to identify patients that could be suitable for the study. During the study 6 visits and 2 telephone contacts are scheduled i.e., Day 1 (baseline visit), Day 4Tel, Week 1, Week 2, Week 4, Week 8, Week 12 and Week 16Tel (End of Study). Patients will be randomly assigned to study drug, after they meet all of the inclusion criteria and none of the exclusion criteria. Patients will receive treatment for 12 weeks, either anakinra or placebo. Patients will be randomized to anakinra in a dose of either 2 or 4 mg/kg/day, with a maximum dose of 100 or 200 mg once daily, respectively. Patients will be randomized to placebo with corresponding volumes for each of the two anakinra dose levels.
Interventions
BIOLOGICALanakinra
sub cutaneous injection
DRUGPlacebo
sub cutaneous injection
Sponsors
Swedish Orphan Biovitrum
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent. 2. Male and female patients with a body weight ≥ 10 kg. 3. Diagnosis of Still's disease. 4. If currently on glucocorticoid treatment, a stable dose for at least 1 week prior to randomization. 5. If currently on methotrexate treatment, a stable dose for at least 8 weeks prior to randomization. 6. Active disease. 7. Female patients of childbearing potential must use an effective method of contraception during the study (abstinence being a possible option) as well as present a negative pregnancy test prior to randomization. 8. Negative interferon-gamma release assay or Purified protein derivative ( PPD) test within 2 months prior to randomization. If not available, a test should be performed at day of randomization.
Exclusion criteria
1. Diagnosis of Still's disease more than 6 months prior to randomization. 2. Previous randomization into this study. 3. Participation in another concurrent clinical interventional study within 30 days of randomization. 4. Treatment with an investigational drug within 5 half-lives prior to randomization. 5. Previous or current treatment with anakinra, canakinumab or any other IL-1 inhibitor. 6. Use of the following therapies prior to randomization: * Narcotic analgesics within 24 hours prior to randomization. * Dapsone or etanercept within 3 weeks prior to randomization. * Intraarticular, intramuscular or intravenous administration of glucocorticoids or intravenous immunoglobulin (Ig) within 4 weeks prior to randomization. * Intravenous Ig with proven Still's disease modifying effect, leflunomide, infliximab or adalimumab within 8 weeks prior to randomization. * Thalidomide, cyclosporine, mycophenolate mofetil, 6-mercaptopurine, azathioprine, cyclophosphamide, chlorambucil or any other immunosuppressant within 12 weeks prior to randomization. * Tocilizumab within 12 weeks prior to randomization or any other immunomodulatory medication within 4 half-lives prior to randomization * Rituximab within 26 weeks prior to randomization. 7. Live vaccines within 1 month prior to randomization. 8. Known presence or suspicion of active, chronic or recurrent bacterial, fungal or viral infections, including tuberculosis, HIV infection or hepatitis B or C infection. 9. Clinical evidence of liver disease or liver injury. 10. Presence of severe renal function impairment. 11. Presence of neutropenia. 12. Presence or suspicion of MAS at baseline. 13. A diagnosis of MAS within the last 2 months prior to randomization. 14. History of malignancy within 5 years. 15. Known hypersensitivity to E coli-derived proteins, or any components of Kineret® (anakinra). 16. Pregnant or lactating women. 17. Foreseeable inability to cooperate with given instructions or study procedures. 18. Presence of any medical or psychological condition or laboratory result that in the opinion of the investigator can interfere with the patient's ability to comply with the protocol requirements or makes the patient not appropriate for inclusion to the study and treatment with IMP.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of ACR30 Responders With Absence of Fever Attributable to the Disease During the 7 Days Preceding Week 2. | Week 2 | ACR30 response is defined as an improvement of ≥ 30% from baseline in at least 3 of any 6 variables listed below. Also no more than 1 of the 6 variables may worsen by \>30% from baseline. (ACR: American College of Rheumatology) 1. Physician global assessment of disease activity - Assessed on a Visual Analogue Scale (VAS) from no disease activity (0 mm) to very severe disease activity (100 mm). 2. Patient/parent global assessment of overall well-being - Assessed on a VAS from very well (0 mm) to very poor (100 mm). 3. Number of joints with active arthritis. 4. Number of joints with limitation of motion. 5. Assessment of physical function - Patient Reported Outcome instruments : Childhood Health Assessment Questionnaire (CHAQ) /Stanford Health Assessment Questionnaire (SHAQ). 6. C-Reactive Protein (CRP) (mg/L). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of ACR50 Responders With Absence of Fever During 24 Hours Preceding Week 1. | Week 1 | ACR50 response is defined as an improvement of ≥ 50% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by \>30% from baseline. |
| Proportion of ACR70 Responders With Absence of Fever During 24 Hours Preceding Week 1. | Week 1 | ACR70 response is defined as an improvement of ≥ 70% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by \>30% from baseline. |
| Proportion of ACR90 Responders With Absence of Fever During 24 Hours Preceding Week 1. | Week 1 | ACR90 response is defined as an improvement of ≥ 90% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by \>30% from baseline. |
| Proportion of ACR50 Responders With Absence of Fever During 7 Days Preceding Week 2. | Week 2 | ACR50 response is defined as an improvement of ≥ 50% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by \>30% from baseline. |
| Proportion of ACR70 Responders With Absence of Fever During 7 Days Preceding Week 2. | Week 2 | ACR70 response is defined as an improvement of ≥ 70% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome. Also no more than 1 of the 6 variables may worsen by \>30% from baseline. |
| Proportion of ACR90 Responders With Absence of Fever During 7 Days Preceding Week 2. | Week 2 | ACR90 response is defined as an improvement of ≥ 90% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome . Also no more than 1 of the 6 variables may worsen by \>30% from baseline. |
| Proportion of Responders in Physician Global Assessment of Disease Activity. | Week 2 | Assessed on a VAS from no disease activity (0 mm) to very severe disease activity (100 mm). Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline. Only improvement of ≥90% at Week 2 reported here. |
| Proportion of Responders in Patient/Parent Global Assessment of Overall Well-being. | Week 2 | Assessed on a VAS from very well (0 mm) to very poor. (100 mm). Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline.Only improvement of ≥90% at Week 2 reported here. |
| Proportion of Responders in Number of Joints With Active Arthritis. | Week 2 | Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline.Only improvement of ≥90% at Week 2 reported here. |
| Proportion of Responders in Number of Joints With Limitation of Motion. | Week 2 | Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline.Only improvement of ≥90% at Week 2 reported here. |
| Proportion of Responders in Assessment of Physical Function (CHAQ/SHAQ). | Week 2 | Childhood Health Assessment Questionnaire (CHAQ) and Stanford Health Assessment Questionnaire (SHAQ) assess physical and functional status (see Clinical protocol section 6.5.4.1.5). Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline. Only improvement of ≥90% at Week 2 reported here. |
| Proportion of Responders in CRP (mg/L). | Week 2 | Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline. Only improvement of ≥90% at Week 2 reported here. |
| Proportion of Patients With Absence of Fever During the 7 Days Preceding Week 2. | Week 2 | Proportion of patients with absence of fever during the 7 days preceding Week 2. |
| Proportion of Patients With Absence of Fever During the 24 Hours Preceding Week 1. | Week 1 | Absence of fever during the 24 hours preceding week 1. |
| Change From Baseline in Physician Global Assessment of Disease Activity at Week 1. | Day 1 and Week 1 | Change from baseline in Physician global assessment of disease activity measured on a VAS 0 (very well)-100 (very poor) at Week 1. |
| Change From Baseline in Patient/Parent Global Assessment of Overall Well-being at Week 1. | Day 1 and Week 1 | Change from baseline in patient/parent global assessment of overall well-being measured on a VAS 0 (very well)-100 (very poor) at Week 1. |
| Change From Baseline in CRP. | Day 1 and Week 1 | Change from baseline in C-Reactive Protein (CRP). CRP is measured in mg/L. |
| Proportion of Patients With Sustained ACR30, ACR50, ACR70 and ACR90 Response. | Week 12 | Proportion of patients that still meet the corresponding week 2 response with absence of fever in the preceding 7 days. Only the strictest criteria, ACR90, is reported here. |
| Proportion of Patients With Sustained ACR30, ACR50, ACR70 and ACR90 Response in Relation to Glucocorticoid Tapering. | Week 2, Week 4, Week 8 and Week 12 | Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available. |
| Proportion of Patients With Absence of Rash. | Week 2 | Absence of rash is evaluated 24 hours preceding Week 1 and 7 days preceding Week 2, Week 4, Week 8 and Week 12. Only data at Week 2 reported here. |
| Change From Baseline in Hemoglobin (Hb). Results at Week 2 Reported Here. | Week 2 | Change from baseline in Hemoglobin (Hb). Results at Week 2 reported here. |
| Change From Baseline in Platelet Count. | Week 2 | Change from baseline in platelet count. Results at Week 2 reported here. |
| Change From Baseline in Ferritin. | Week 2 | Change from baseline in ferritin. Results at Week 2 reported here. |
| Change From Baseline in Patient/Parent Global Assessment of Disease Related Pain. | Week 2 | Assessed on a VAS from no pain (0 mm) to very severe pain (100 mm). |
| Time to Study Drug Discontinuation for Any Reason. | From Day 1 to Week12 | Time to study drug discontinuation was analyzed using Kaplan-Meier curves. Number of patients with premature study drug discontinuation for any reason is reported here. |
| Time to Study Drug Discontinuation Due to Lack of Efficacy or Progressive Disease. | From Day 1 to Week12 | Proportion of study drug discontinuation due to lack of efficacy or progressive disease was analyzed using Kaplan-Meier curves. Number of patients discontinuing study drug due to lack of efficacy or progressive disease is reported here. |
| Proportion of Patients Who Have Initiated Tapering of Glucocorticoids. | From Week 2 to Week12 | Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available |
| Proportion of Patients That Have Decreased the Glucocorticoid Dose With at Least 50% From Baseline. | From Week 2 to Week12 | Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available |
| Percentage Decrease of the Glucocorticoid Dose From Baseline. | From Day 1 to Week12 | Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available |
| Proportion of Patients With at Least One Adverse Event. | From Day 1 to Week 16 | All adverse events collected from start of study treatment up to 28 days after stopping study treatment. |
| Proportion of Patients With at Least One Serious Adverse Event Including Death. | From Informed consent to Week 16 | Serious adverse events (SAEs) will be collected from informed consent up to 28 days after stopping study treatment. |
| Proportion of Patients With Macrophage Activation Syndrome (MAS). | From Day 1 to Week 16 | Proportion of patients with Macrophage Activation Syndrome (MAS). |
| Proportion of Patients With Antidrug Antibodies (ADA) Against Anakinra. | Week 2 | Proportion of patients with antidrug antibodies (ADA) against anakinra. |
| Proportion of Patients With Neutralizing Antibodies. | Week 2 | Confirmed ADA positive samples will be analyzed for the presence of neutralizing antibodies. |
| Anakinra Serum Pre-dose Concentrations. | Week 2 | Week 2 reported here. |
| Anakinra Serum Pharmacokinetic Parameters: Cmax, | Week 12 | PK parameters only available for 2 patients. |
| Anakinra Serum Pharmacokinetic Parameters, Tmax and T½ | Week 12 | PK parameters only available for 2 patients |
| Anakinra Serum Pharmacokinetic Parameter: AUC 0-24 h | Week 12 | PK parameters only available for 2 patients |
| Anakinra Serum Pharmacokinetic Parameter: CL/F | Week 12 | Pharmacokinetic parameters only available for 2 patients |
| Anakinra Serum Pharmacokinetic Parameter: Vd/F | Week 12 | PK parameters only available for 2 patients |
| Change From Baseline in JADAS27. | Week 2 | Juvenile Arthritis Disease Activity Score (JADAS) includes 4 measures: physician global assessment of disease activity, patient or parent global assessment of overall well-being, 27 active joint count, and CRP. The JADAS27 includes the 27 joints. JADAS27 is calculated as the sum of its four components, physician global assessment of disease activity converted to cm from the VAS (0=no activity, 10=maximum activity); patient global assessment of well-being converted to cm from the VAS (0=very well, 10=very poor); active joint count (0-27); and CRP. Prior to calculation CRP is truncated to a 0 - 10 scale according to the following formula: (CRP (mg/l) -10)/10. Before calculation, CRP values \<10 mg/l are converted to 10 and CRP values \>110 mg/l are converted to 110. The JADAS27 tool yields a global score of 0-57. Only results from Week 2 reported here. |
| Proportion of ACR30 Responders With Absence of Fever During 24 Hours Preceding Week 1. | Week 1 | ACR30 response is defined as an improvement of ≥ 30% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by \>30% from baseline. |
| Proportion of Patients With Inactive Disease. | Week 12 | Inactive disease is a composite of the following parameters: no joints with active arthritis, no fever, no rash, no serositis, no splenomegaly, no generalized lymphadenopathy attributable to Still's disease, CRP level within normal limits, physician's global assessment of disease activity score below 10 mm on a 100 mm VAS and a documented morning stiffness ≤15 minutes. |
| Change From Baseline in IL-6. | Week 2 | Only results from Week 2 reported here. |
| Change From Baseline in IL-18. | Week 2 | Only results from Week 2 reported here |
| Change From Baseline in Serum Calprotectin. | Week 2 | Change from baseline in serum calprotectin. Only results from Week 2 reported here |
| Change From Baseline in Neopterin. | Week 2 | Only results from Week 2 reported here |
| Number of Days Off School or Work Due to Still's Disease. | Week 2 | Number of days off school or work due to Still's disease week 1-2. |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Corresponding volume to anakinra 2 mg/kg/day or 4 mg/kg/day
Placebo: sub cutaneous injection | 5 |
| Anakinra 2 mg/kg/day (max 100 mg/day) or 4 mg/kg/day (max 200 mg/day)
anakinra: sub cutaneous injection | 6 |
| Total | 11 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 0 | 1 |
| Overall Study | Lack of Efficacy | 0 | 2 |
| Overall Study | Progressive disease | 0 | 2 |
| Overall Study | Withdrawal by Subject | 0 | 1 |
Baseline characteristics
| Characteristic | Total | Placebo | Anakinra |
|---|---|---|---|
| Age, Continuous | 13.3 years STANDARD_DEVIATION 16 | 14.4 years STANDARD_DEVIATION 13.2 | 12.3 years STANDARD_DEVIATION 19.3 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 9 Participants | 4 Participants | 5 Participants |
| Region of Enrollment United States | 11 participants | 5 participants | 6 participants |
| Sex: Female, Male Female | 5 Participants | 3 Participants | 2 Participants |
| Sex: Female, Male Male | 6 Participants | 2 Participants | 4 Participants |
| Still's disease symptom duration | 74.2 Days STANDARD_DEVIATION 69.1 | 32.4 Days STANDARD_DEVIATION 18.7 | 109.0 Days STANDARD_DEVIATION 78 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 6 |
| other Total, other adverse events | 6 / 6 | 4 / 6 |
| serious Total, serious adverse events | 0 / 6 | 1 / 6 |
Outcome results
Primary
Proportion of ACR30 Responders With Absence of Fever Attributable to the Disease During the 7 Days Preceding Week 2.
ACR30 response is defined as an improvement of ≥ 30% from baseline in at least 3 of any 6 variables listed below. Also no more than 1 of the 6 variables may worsen by \>30% from baseline. (ACR: American College of Rheumatology) 1. Physician global assessment of disease activity - Assessed on a Visual Analogue Scale (VAS) from no disease activity (0 mm) to very severe disease activity (100 mm). 2. Patient/parent global assessment of overall well-being - Assessed on a VAS from very well (0 mm) to very poor (100 mm). 3. Number of joints with active arthritis. 4. Number of joints with limitation of motion. 5. Assessment of physical function - Patient Reported Outcome instruments : Childhood Health Assessment Questionnaire (CHAQ) /Stanford Health Assessment Questionnaire (SHAQ). 6. C-Reactive Protein (CRP) (mg/L).
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of ACR30 Responders With Absence of Fever Attributable to the Disease During the 7 Days Preceding Week 2. | 6 Participants |
| Placebo | Proportion of ACR30 Responders With Absence of Fever Attributable to the Disease During the 7 Days Preceding Week 2. | 0 Participants |
p-value: 0.002295% CI: [0.42, 1]Fisher Exact
Secondary
Anakinra Serum Pharmacokinetic Parameter: AUC 0-24 h
PK parameters only available for 2 patients
Time frame: Week 12
Population: PK parameters only available for 2 anakinra treated patients
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Anakinra Serum Pharmacokinetic Parameter: AUC 0-24 h | 18483.3 h*ng/mL | Standard Deviation 15708.4 |
Secondary
Anakinra Serum Pharmacokinetic Parameter: CL/F
Pharmacokinetic parameters only available for 2 patients
Time frame: Week 12
Population: Pharmacokinetic parameters only available for 2 anakinra treated patients
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Anakinra Serum Pharmacokinetic Parameter: CL/F | 170.80 mL/h*kg | Standard Deviation 45.69 |
Secondary
Anakinra Serum Pharmacokinetic Parameters: Cmax,
PK parameters only available for 2 patients.
Time frame: Week 12
Population: PK parameters only available for 2 anakinra treated patients.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Anakinra Serum Pharmacokinetic Parameters: Cmax, | 1990.0 ng/mL | Standard Deviation 1315.2 |
Secondary
Anakinra Serum Pharmacokinetic Parameters, Tmax and T½
PK parameters only available for 2 patients
Time frame: Week 12
Population: PK parameters only available for 2 patients
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Anakinra Serum Pharmacokinetic Parameters, Tmax and T½ | Tmax | 3.06 hours | Standard Deviation 1.33 |
| Placebo | Anakinra Serum Pharmacokinetic Parameters, Tmax and T½ | T½ | 5.23 hours | Standard Deviation 1.01 |
Secondary
Anakinra Serum Pharmacokinetic Parameter: Vd/F
PK parameters only available for 2 patients
Time frame: Week 12
Population: PK parameters only available for 2 anakinra treated patients
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Anakinra Serum Pharmacokinetic Parameter: Vd/F | 1254.52 mL/kg | Standard Deviation 95.57 |
Secondary
Anakinra Serum Pre-dose Concentrations.
Week 2 reported here.
Time frame: Week 2
Population: No data available for the placebo group as they did not receive anakinra.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Anakinra Serum Pre-dose Concentrations. | 157 ng/mL | Standard Deviation 134 |
Secondary
Change From Baseline in CRP.
Change from baseline in CRP. Results at Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in CRP. | -126.670 mg/L | Standard Deviation 66.697 |
| Placebo | Change From Baseline in CRP. | -33.904 mg/L | Standard Deviation 64.393 |
Secondary
Change From Baseline in CRP.
Change from baseline in C-Reactive Protein (CRP). CRP is measured in mg/L.
Time frame: Day 1 and Week 1
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in CRP. | -109.6 mg/L | Standard Deviation 63.4 |
| Placebo | Change From Baseline in CRP. | -22.7 mg/L | Standard Deviation 47.1 |
Secondary
Change From Baseline in Ferritin.
Change from baseline in ferritin. Results at Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in Ferritin. | -390.364 ug/L | Standard Deviation 387.521 |
| Placebo | Change From Baseline in Ferritin. | -49.383 ug/L | Standard Deviation 51.776 |
Secondary
Change From Baseline in Hemoglobin (Hb). Results at Week 2 Reported Here.
Change from baseline in Hemoglobin (Hb). Results at Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in Hemoglobin (Hb). Results at Week 2 Reported Here. | 1.57 g/dL | Standard Deviation 0.86 |
| Placebo | Change From Baseline in Hemoglobin (Hb). Results at Week 2 Reported Here. | -0.80 g/dL | Standard Deviation 1.01 |
Secondary
Change From Baseline in IL-18.
Only results from Week 2 reported here
Time frame: Week 2
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in IL-18. | -7968.0 ng/L | Standard Deviation 7564.4 |
| Placebo | Change From Baseline in IL-18. | -20701.7 ng/L | Standard Deviation 32766.4 |
Secondary
Change From Baseline in IL-6.
Only results from Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in IL-6. | -30.048 ng/L | Standard Deviation 23.262 |
| Placebo | Change From Baseline in IL-6. | -24.818 ng/L | Standard Deviation 25.94 |
Secondary
Change From Baseline in JADAS27.
Juvenile Arthritis Disease Activity Score (JADAS) includes 4 measures: physician global assessment of disease activity, patient or parent global assessment of overall well-being, 27 active joint count, and CRP. The JADAS27 includes the 27 joints. JADAS27 is calculated as the sum of its four components, physician global assessment of disease activity converted to cm from the VAS (0=no activity, 10=maximum activity); patient global assessment of well-being converted to cm from the VAS (0=very well, 10=very poor); active joint count (0-27); and CRP. Prior to calculation CRP is truncated to a 0 - 10 scale according to the following formula: (CRP (mg/l) -10)/10. Before calculation, CRP values \<10 mg/l are converted to 10 and CRP values \>110 mg/l are converted to 110. The JADAS27 tool yields a global score of 0-57. Only results from Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in JADAS27. | -21.42 score on a scale | Standard Deviation 3.93 |
| Placebo | Change From Baseline in JADAS27. | -15.81 score on a scale | Standard Deviation 4.83 |
Secondary
Change From Baseline in Neopterin.
Only results from Week 2 reported here
Time frame: Week 2
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in Neopterin. | -3.08 nmol/L | Standard Deviation 5.69 |
| Placebo | Change From Baseline in Neopterin. | -8.00 nmol/L | Standard Deviation 10.82 |
Secondary
Change From Baseline in Patient/Parent Global Assessment of Disease Related Pain.
Assessed on a VAS from no pain (0 mm) to very severe pain (100 mm).
Time frame: Week 2
Population: Patients with baseline and week 2 data analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in Patient/Parent Global Assessment of Disease Related Pain. | -55.6 score on a scale | Standard Deviation 27.7 |
| Placebo | Change From Baseline in Patient/Parent Global Assessment of Disease Related Pain. | -33.5 score on a scale | Standard Deviation 28.5 |
Secondary
Change From Baseline in Patient/Parent Global Assessment of Overall Well-being at Week 1.
Change from baseline in patient/parent global assessment of overall well-being measured on a VAS 0 (very well)-100 (very poor) at Week 1.
Time frame: Day 1 and Week 1
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in Patient/Parent Global Assessment of Overall Well-being at Week 1. | -53.7 mm | Standard Deviation 27.7 |
| Placebo | Change From Baseline in Patient/Parent Global Assessment of Overall Well-being at Week 1. | -25.0 mm | Standard Deviation 31.7 |
Secondary
Change From Baseline in Physician Global Assessment of Disease Activity at Week 1.
Change from baseline in Physician global assessment of disease activity measured on a VAS 0 (very well)-100 (very poor) at Week 1.
Time frame: Day 1 and Week 1
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in Physician Global Assessment of Disease Activity at Week 1. | -46.3 mm | Standard Deviation 32.6 |
| Placebo | Change From Baseline in Physician Global Assessment of Disease Activity at Week 1. | -30.0 mm | Standard Deviation 18.5 |
Secondary
Change From Baseline in Platelet Count.
Change from baseline in platelet count. Results at Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in Platelet Count. | -148.2 10^9/L | Standard Deviation 52.3 |
| Placebo | Change From Baseline in Platelet Count. | -26.3 10^9/L | Standard Deviation 139.6 |
Secondary
Change From Baseline in Serum Calprotectin.
Change from baseline in serum calprotectin. Only results from Week 2 reported here
Time frame: Week 2
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Change From Baseline in Serum Calprotectin. | -100.038 mg/L | Standard Deviation 113.349 |
| Placebo | Change From Baseline in Serum Calprotectin. | -26.021 mg/L | Standard Deviation 23.819 |
Secondary
Number of Days Off School or Work Due to Still's Disease.
Number of days off school or work due to Still's disease week 1-2.
Time frame: Week 2
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anakinra | Number of Days Off School or Work Due to Still's Disease. | 0.7 Days | Standard Deviation 1.6 |
| Placebo | Number of Days Off School or Work Due to Still's Disease. | 1.3 Days | Standard Deviation 2.5 |
Secondary
Percentage Decrease of the Glucocorticoid Dose From Baseline.
Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available
Time frame: From Day 1 to Week12
Population: No patients were treated with any systemic glucocorticoids at randomization
Secondary
Proportion of ACR30 Responders With Absence of Fever During 24 Hours Preceding Week 1.
ACR30 response is defined as an improvement of ≥ 30% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by \>30% from baseline.
Time frame: Week 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of ACR30 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 5 Participants |
| Placebo | Proportion of ACR30 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 3 Participants |
Secondary
Proportion of ACR50 Responders With Absence of Fever During 24 Hours Preceding Week 1.
ACR50 response is defined as an improvement of ≥ 50% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by \>30% from baseline.
Time frame: Week 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of ACR50 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 5 Participants |
| Placebo | Proportion of ACR50 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 2 Participants |
Secondary
Proportion of ACR50 Responders With Absence of Fever During 7 Days Preceding Week 2.
ACR50 response is defined as an improvement of ≥ 50% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by \>30% from baseline.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of ACR50 Responders With Absence of Fever During 7 Days Preceding Week 2. | 6 Participants |
| Placebo | Proportion of ACR50 Responders With Absence of Fever During 7 Days Preceding Week 2. | 0 Participants |
Secondary
Proportion of ACR70 Responders With Absence of Fever During 24 Hours Preceding Week 1.
ACR70 response is defined as an improvement of ≥ 70% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by \>30% from baseline.
Time frame: Week 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of ACR70 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 5 Participants |
| Placebo | Proportion of ACR70 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 0 Participants |
Secondary
Proportion of ACR70 Responders With Absence of Fever During 7 Days Preceding Week 2.
ACR70 response is defined as an improvement of ≥ 70% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome. Also no more than 1 of the 6 variables may worsen by \>30% from baseline.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of ACR70 Responders With Absence of Fever During 7 Days Preceding Week 2. | 6 Participants |
| Placebo | Proportion of ACR70 Responders With Absence of Fever During 7 Days Preceding Week 2. | 0 Participants |
Secondary
Proportion of ACR90 Responders With Absence of Fever During 24 Hours Preceding Week 1.
ACR90 response is defined as an improvement of ≥ 90% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by \>30% from baseline.
Time frame: Week 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of ACR90 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 4 Participants |
| Placebo | Proportion of ACR90 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 0 Participants |
Secondary
Proportion of ACR90 Responders With Absence of Fever During 7 Days Preceding Week 2.
ACR90 response is defined as an improvement of ≥ 90% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome . Also no more than 1 of the 6 variables may worsen by \>30% from baseline.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of ACR90 Responders With Absence of Fever During 7 Days Preceding Week 2. | 5 Participants |
| Placebo | Proportion of ACR90 Responders With Absence of Fever During 7 Days Preceding Week 2. | 0 Participants |
Secondary
Proportion of Patients That Have Decreased the Glucocorticoid Dose With at Least 50% From Baseline.
Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available
Time frame: From Week 2 to Week12
Population: No patients were treated with any systemic glucocorticoids at randomization
Secondary
Proportion of Patients Who Have Initiated Tapering of Glucocorticoids.
Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available
Time frame: From Week 2 to Week12
Population: No patients were treated with any systemic glucocorticoids at randomization
Secondary
Proportion of Patients With Absence of Fever During the 24 Hours Preceding Week 1.
Absence of fever during the 24 hours preceding week 1.
Time frame: Week 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Patients With Absence of Fever During the 24 Hours Preceding Week 1. | 6 Participants |
| Placebo | Proportion of Patients With Absence of Fever During the 24 Hours Preceding Week 1. | 4 Participants |
Secondary
Proportion of Patients With Absence of Fever During the 7 Days Preceding Week 2.
Proportion of patients with absence of fever during the 7 days preceding Week 2.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Patients With Absence of Fever During the 7 Days Preceding Week 2. | 6 Participants |
| Placebo | Proportion of Patients With Absence of Fever During the 7 Days Preceding Week 2. | 0 Participants |
Secondary
Proportion of Patients With Absence of Rash.
Absence of rash is evaluated 24 hours preceding Week 1 and 7 days preceding Week 2, Week 4, Week 8 and Week 12. Only data at Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Patients With Absence of Rash. | 5 Participants |
| Placebo | Proportion of Patients With Absence of Rash. | 2 Participants |
Secondary
Proportion of Patients With Antidrug Antibodies (ADA) Against Anakinra.
Proportion of patients with antidrug antibodies (ADA) against anakinra.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Patients With Antidrug Antibodies (ADA) Against Anakinra. | 6 Participants |
| Placebo | Proportion of Patients With Antidrug Antibodies (ADA) Against Anakinra. | 1 Participants |
Secondary
Proportion of Patients With at Least One Adverse Event.
All adverse events collected from start of study treatment up to 28 days after stopping study treatment.
Time frame: From Day 1 to Week 16
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Patients With at Least One Adverse Event. | 6 Participants |
| Placebo | Proportion of Patients With at Least One Adverse Event. | 4 Participants |
Secondary
Proportion of Patients With at Least One Serious Adverse Event Including Death.
Serious adverse events (SAEs) will be collected from informed consent up to 28 days after stopping study treatment.
Time frame: From Informed consent to Week 16
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Patients With at Least One Serious Adverse Event Including Death. | 0 Participants |
| Placebo | Proportion of Patients With at Least One Serious Adverse Event Including Death. | 1 Participants |
Secondary
Proportion of Patients With Inactive Disease.
Inactive disease is a composite of the following parameters: no joints with active arthritis, no fever, no rash, no serositis, no splenomegaly, no generalized lymphadenopathy attributable to Still's disease, CRP level within normal limits, physician's global assessment of disease activity score below 10 mm on a 100 mm VAS and a documented morning stiffness ≤15 minutes.
Time frame: Week 12
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Patients With Inactive Disease. | 3 Participants |
| Placebo | Proportion of Patients With Inactive Disease. | 0 Participants |
Secondary
Proportion of Patients With Macrophage Activation Syndrome (MAS).
Proportion of patients with Macrophage Activation Syndrome (MAS).
Time frame: From Day 1 to Week 16
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Patients With Macrophage Activation Syndrome (MAS). | 0 Participants |
| Placebo | Proportion of Patients With Macrophage Activation Syndrome (MAS). | 0 Participants |
Secondary
Proportion of Patients With Neutralizing Antibodies.
Confirmed ADA positive samples will be analyzed for the presence of neutralizing antibodies.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Patients With Neutralizing Antibodies. | 0 Participants |
| Placebo | Proportion of Patients With Neutralizing Antibodies. | 0 Participants |
Secondary
Proportion of Patients With Sustained ACR30, ACR50, ACR70 and ACR90 Response.
Proportion of patients that still meet the corresponding week 2 response with absence of fever in the preceding 7 days. Only the strictest criteria, ACR90, is reported here.
Time frame: Week 12
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Patients With Sustained ACR30, ACR50, ACR70 and ACR90 Response. | 6 Participants |
| Placebo | Proportion of Patients With Sustained ACR30, ACR50, ACR70 and ACR90 Response. | 0 Participants |
Secondary
Proportion of Patients With Sustained ACR30, ACR50, ACR70 and ACR90 Response in Relation to Glucocorticoid Tapering.
Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available.
Time frame: Week 2, Week 4, Week 8 and Week 12
Population: No patients were treated with any systemic glucocorticoids at randomization
Secondary
Proportion of Responders in Assessment of Physical Function (CHAQ/SHAQ).
Childhood Health Assessment Questionnaire (CHAQ) and Stanford Health Assessment Questionnaire (SHAQ) assess physical and functional status (see Clinical protocol section 6.5.4.1.5). Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline. Only improvement of ≥90% at Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Responders in Assessment of Physical Function (CHAQ/SHAQ). | 4 Participants |
| Placebo | Proportion of Responders in Assessment of Physical Function (CHAQ/SHAQ). | 0 Participants |
Secondary
Proportion of Responders in CRP (mg/L).
Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline. Only improvement of ≥90% at Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Responders in CRP (mg/L). | 5 Participants |
| Placebo | Proportion of Responders in CRP (mg/L). | 0 Participants |
Secondary
Proportion of Responders in Number of Joints With Active Arthritis.
Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline.Only improvement of ≥90% at Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Responders in Number of Joints With Active Arthritis. | 3 Participants |
| Placebo | Proportion of Responders in Number of Joints With Active Arthritis. | 2 Participants |
Secondary
Proportion of Responders in Number of Joints With Limitation of Motion.
Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline.Only improvement of ≥90% at Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Responders in Number of Joints With Limitation of Motion. | 4 Participants |
| Placebo | Proportion of Responders in Number of Joints With Limitation of Motion. | 2 Participants |
Secondary
Proportion of Responders in Patient/Parent Global Assessment of Overall Well-being.
Assessed on a VAS from very well (0 mm) to very poor. (100 mm). Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline.Only improvement of ≥90% at Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Responders in Patient/Parent Global Assessment of Overall Well-being. | 4 Participants |
| Placebo | Proportion of Responders in Patient/Parent Global Assessment of Overall Well-being. | 0 Participants |
Secondary
Proportion of Responders in Physician Global Assessment of Disease Activity.
Assessed on a VAS from no disease activity (0 mm) to very severe disease activity (100 mm). Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from baseline. Only improvement of ≥90% at Week 2 reported here.
Time frame: Week 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Proportion of Responders in Physician Global Assessment of Disease Activity. | 4 Participants |
| Placebo | Proportion of Responders in Physician Global Assessment of Disease Activity. | 0 Participants |
Secondary
Time to Study Drug Discontinuation Due to Lack of Efficacy or Progressive Disease.
Proportion of study drug discontinuation due to lack of efficacy or progressive disease was analyzed using Kaplan-Meier curves. Number of patients discontinuing study drug due to lack of efficacy or progressive disease is reported here.
Time frame: From Day 1 to Week12
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Time to Study Drug Discontinuation Due to Lack of Efficacy or Progressive Disease. | 0 Participants |
| Placebo | Time to Study Drug Discontinuation Due to Lack of Efficacy or Progressive Disease. | 4 Participants |
Secondary
Time to Study Drug Discontinuation for Any Reason.
Time to study drug discontinuation was analyzed using Kaplan-Meier curves. Number of patients with premature study drug discontinuation for any reason is reported here.
Time frame: From Day 1 to Week12
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Anakinra | Time to Study Drug Discontinuation for Any Reason. | 0 Participants |
| Placebo | Time to Study Drug Discontinuation for Any Reason. | 5 Participants |